Pinnacle Associates’s Intellia Therapeutics NTLA Stock Holding History

Pinnacle Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.87M	Sell	145,512 -3,719	-2%	-$47.4K	0.02%	406
2025 Q4	$1.34M	Sell	149,231 -14,479	-9%	-$199K	0.02%	470
2025 Q3	$2.83M	Sell	163,710 -5,640	-3%	-$69.5K	0.04%	342
2025 Q2	$1.59M	Sell	169,350 -45,470	-21%	-$373K	0.02%	421
2025 Q1	$1.53M	Sell	214,820 -5,352	-2%	-$54.1K	0.02%	416
2024 Q4	$2.57M	Buy	+220,172	New	+$3.44M	0.03%	339
2024 Q3	–	Sell	-251,078	Closed	-$5.62M	–	833
2024 Q2	$5.62M	Sell	251,078 -4,638	-2%	-$110K	0.09%	232
2024 Q1	$7.03M	Buy	+255,716	New	+$7.1M	0.11%	202

Other funds holding NTLA

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments

Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return